{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:33:39Z","timestamp":1776454419812,"version":"3.51.2"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11883-022-01077-9","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T08:04:41Z","timestamp":1673078681000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-907X","authenticated-orcid":false,"given":"Wann Jia","family":"Loh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"issue":"1","key":"1077_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"25","key":"1077_CR2","first-page":"e1046","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046\u201381.","journal-title":"Circulation"},{"issue":"11","key":"1077_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41580-021-00389-z","volume":"22","author":"JJ Dowling","year":"2021","unstructured":"Dowling JJ, Weihl CC, Spencer MJ. Molecular and cellular basis of genetically inherited skeletal muscle disorders. Nat Rev Mol Cell Biol. 2021;22(11):713\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1077_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm9010022","volume":"9","author":"RM Turner","year":"2019","unstructured":"Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9(1):22.","journal-title":"J Clin Med"},{"issue":"2","key":"1077_CR5","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"1077_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"key":"1077_CR7","doi-asserted-by":"crossref","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J\u00a02022.","DOI":"10.1093\/eurheartj\/ehac015"},{"issue":"13","key":"1077_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681\u201390.","journal-title":"JAMA"},{"issue":"8","key":"1077_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","volume":"114","author":"LR Brunham","year":"2018","unstructured":"Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res. 2018;114(8):1073\u201381.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1077_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","volume":"218","author":"G Ruano","year":"2011","unstructured":"Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011;218(2):451\u20136.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1077_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/acr.21879","volume":"65","author":"MT de Moraes","year":"2013","unstructured":"de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken). 2013;65(5):793\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1077_CR12","first-page":"82","volume":"32","author":"FH de Souza","year":"2014","unstructured":"de Souza FH, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol. 2014;32(1):82\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1077_CR13","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1007\/s10067-021-05751-2","volume":"40","author":"C Zhen","year":"2021","unstructured":"Zhen C, Wang Y, Wang H, Wang X. The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol. 2021;40(10):4101\u20138.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1077_CR14","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3899\/jrheum.090061","volume":"36","author":"A Tisseverasinghe","year":"2009","unstructured":"Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36(9):1943\u20136.","journal-title":"J Rheumatol"},{"issue":"3","key":"1077_CR15","doi-asserted-by":"publisher","first-page":"e33442","DOI":"10.1371\/journal.pone.0033442","volume":"7","author":"B Zoller","year":"2012","unstructured":"Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE. 2012;7(3):e33442.","journal-title":"PLoS ONE"},{"issue":"5","key":"1077_CR16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjd.12245","volume":"168","author":"YT Lai","year":"2013","unstructured":"Lai YT, Dai YS, Yen MF, et al. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow-up study. Br J Dermatol. 2013;168(5):1054\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1077_CR17","first-page":"461","volume":"55","author":"SK Rai","year":"2016","unstructured":"Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford). 2016;55(3):461\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1077_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689\u2013701.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1077_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10741-019-09909-8","volume":"26","author":"AH Opinc","year":"2021","unstructured":"Opinc AH, Makowski MA, Lukasik ZM, Makowska JS. Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies? Heart Fail Rev. 2021;26(1):111\u201325.","journal-title":"Heart Fail Rev"},{"issue":"7","key":"1077_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/clc.23375","volume":"43","author":"SS Bae","year":"2020","unstructured":"Bae SS, Oganesian B, Golub I, Charles-Schoeman C. Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: a retrospective study. Clin Cardiol. 2020;43(7):732\u201342.","journal-title":"Clin Cardiol"},{"issue":"2","key":"1077_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00296-018-4215-x","volume":"39","author":"IBP Borges","year":"2019","unstructured":"Borges IBP, Shinjo SK. Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatol Int. 2019;39(2):311\u20136.","journal-title":"Rheumatol Int"},{"issue":"21","key":"1077_CR22","doi-asserted-by":"publisher","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","volume":"96","author":"S Shelly","year":"2021","unstructured":"Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021;96(21):e2653\u201361.","journal-title":"Neurology"},{"issue":"1","key":"1077_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","volume":"24","author":"M Needham","year":"2014","unstructured":"Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24(1):4\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"1077_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mus.20567","volume":"34","author":"GD Vladutiu","year":"2006","unstructured":"Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153\u201362.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1077_CR25","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/ijms22042070","volume":"22","author":"GM Camerino","year":"2021","unstructured":"Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-induced myopathy: translational studies from preclinical to clinical evidence. Int J Mol Sci. 2021;22(4):2070.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"1077_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/bph.15678","volume":"179","author":"Z Sun","year":"2022","unstructured":"Sun Z, Xu D, Zhao L, et al. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: the promotion of myostatin degradation. Br J Pharmacol. 2022;179(6):1237\u201350.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1077_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/CPJ.0000000000000645","volume":"9","author":"B Schoser","year":"2019","unstructured":"Schoser B, Montagnese F, Bassez G, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract. 2019;9(4):343\u201353.","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"1077_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1517\/14740338.2014.937422","volume":"13","author":"HI Keen","year":"2014","unstructured":"Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf. 2014;13(9):1227\u201339.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1077_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mus.26637","volume":"60","author":"V Gras-Champel","year":"2019","unstructured":"Gras-Champel V, Batteux B, Masmoudi K, Liabeuf S. Statin-induced myasthenia: a disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database. Muscle Nerve. 2019;60(4):382\u20136.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1077_CR30","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1097\/MD.0000000000000416","volume":"94","author":"Y Watanabe","year":"2015","unstructured":"Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore). 2015;94(4):e416.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1077_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/mus.21074","volume":"38","author":"SJ Oh","year":"2008","unstructured":"Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38(3):1101\u20137.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1077_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mus.25155","volume":"54","author":"R Khalid","year":"2016","unstructured":"Khalid R, Ibad A, Thompson PD. Statins and myasthenia gravis. Muscle Nerve. 2016;54(3):509.","journal-title":"Muscle Nerve"},{"issue":"9334","key":"1077_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(02)09846-X","volume":"360","author":"B Parmar","year":"2002","unstructured":"Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002;360(9334):717.","journal-title":"Lancet"},{"key":"1077_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","volume":"13","author":"M Krenn","year":"2020","unstructured":"Krenn M, Grisold A, Wohlfarth P, et al. Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments. Front Mol Neurosci. 2020;13:156.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"1077_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17482960802031092","volume":"9","author":"L Zinman","year":"2008","unstructured":"Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223\u20138.","journal-title":"Amyotroph Lateral Scler"},{"issue":"4","key":"1077_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00228-018-2587-1","volume":"75","author":"D Macias Saint-Gerons","year":"2019","unstructured":"Macias Saint-Gerons D, Castro JL. Amyotrophic lateral sclerosis associated with statins A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Eur J Clin Pharmacol. 2019;75(4):587\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"30","key":"1077_CR37","doi-asserted-by":"publisher","first-page":"e26751","DOI":"10.1097\/MD.0000000000026751","volume":"100","author":"MC Chang","year":"2021","unstructured":"Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2021;100(30):e26751.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"1077_CR38","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1007\/s10072-022-06131-7","volume":"43","author":"N Hu","year":"2022","unstructured":"Hu N, Ji H. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2022;43(9):5189\u201399.","journal-title":"Neurol Sci"},{"issue":"8","key":"1077_CR39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/ene.14300","volume":"27","author":"J Schumacher","year":"2020","unstructured":"Schumacher J, Peter RS, Nagel G, et al. Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol. 2020;27(8):1405\u201314.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1077_CR40","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00415-010-5805-z","volume":"258","author":"J Dorst","year":"2011","unstructured":"Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613\u20137.","journal-title":"J Neurol"},{"issue":"13","key":"1077_CR41","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","volume":"70","author":"L Dupuis","year":"2008","unstructured":"Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004\u20139.","journal-title":"Neurology"},{"issue":"7","key":"1077_CR42","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/aje\/kwac054","volume":"191","author":"MG Weisskopf","year":"2022","unstructured":"Weisskopf MG, Levy J, Dickerson AS, Paganoni S, Leventer-Roberts M. Statin medications and amyotrophic lateral sclerosis incidence and mortality. Am J Epidemiol. 2022;191(7):1248\u201357.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1077_CR43","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/hmg\/ddy384","volume":"28","author":"P Zeng","year":"2019","unstructured":"Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688\u201397.","journal-title":"Hum Mol Genet"},{"issue":"202","key":"1077_CR44","first-page":"201 e201","volume":"67","author":"X Chen","year":"2018","unstructured":"Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67(202):201 e201-202 e206.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"1077_CR45","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00415-015-7971-5","volume":"262","author":"A Mignarri","year":"2015","unstructured":"Mignarri A, Malandrini A, Del Puppo M, et al. Treatment of SPG5 with cholesterol-lowering drugs. J Neurol. 2015;262(12):2783\u20135.","journal-title":"J Neurol"},{"key":"1077_CR46","doi-asserted-by":"crossref","unstructured":"Loh WJ, Watts GF. The inherited hypercholesterolemias. Endocrinology and Metabolism Clinics of North America. 2022.","DOI":"10.1016\/j.ecl.2022.02.006"},{"issue":"6","key":"1077_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","volume":"40","author":"G Salen","year":"2017","unstructured":"Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017;40(6):771\u201381.","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"1077_CR48","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1468-1331.2011.03439.x","volume":"18","author":"B Pilo-de-la-Fuente","year":"2011","unstructured":"Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18(10):1203\u201311.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1077_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drudis.2016.09.001","volume":"22","author":"DM Muntean","year":"2017","unstructured":"Muntean DM, Thompson PD, Catapano AL, et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017;22(1):85\u201396.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1077_CR50","first-page":"16","volume":"10","author":"R Deichmann","year":"2010","unstructured":"Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10(1):16\u201321.","journal-title":"Ochsner J"},{"issue":"23","key":"1077_CR51","doi-asserted-by":"publisher","first-page":"9229","DOI":"10.3390\/ijms21239299","volume":"21","author":"H Manzar","year":"2020","unstructured":"Manzar H, Abdulhussein D, Yap TE, Cordeiro MF. Cellular consequences of coenzyme Q10 deficiency in neurodegeneration of the retina and brain. Int J Mol Sci. 2020;21(23):9229.","journal-title":"Int J Mol Sci."},{"issue":"9412","key":"1077_CR52","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","volume":"363","author":"B Moosmann","year":"2004","unstructured":"Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363(9412):892\u20134.","journal-title":"Lancet"},{"issue":"2","key":"1077_CR53","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1152\/japplphysiol.01003.2020","volume":"131","author":"M Haseeb","year":"1985","unstructured":"Haseeb M. Thompson PD 2021 The effect of statins on RyR and RyR-associated disease. J Appl Physiol (1985). 1985;131(2):661\u201371.","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"1077_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019;124(2):328\u201350.","journal-title":"Circ Res"},{"issue":"5\u20136","key":"1077_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00438-013-0741-0","volume":"288","author":"JM Moser","year":"2013","unstructured":"Moser JM, Bigini P, Schmitt-John T. The wobbler mouse, an ALS animal model. Mol Genet Genomics. 2013;288(5\u20136):207\u201329.","journal-title":"Mol Genet Genomics"},{"issue":"6","key":"1077_CR56","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","volume":"92","author":"J Bosel","year":"2005","unstructured":"Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92(6):1386\u201398.","journal-title":"J Neurochem"},{"issue":"4","key":"1077_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","volume":"20","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"1077_CR58","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1077_CR59","doi-asserted-by":"publisher","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","volume":"10","author":"Y Ge","year":"2015","unstructured":"Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3- methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. Plos One. 2015;10(10):e0141616.","journal-title":"Plos One"},{"issue":"9","key":"1077_CR60","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757\u201366.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1077_CR61","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1212\/NXI.0000000000000124","volume":"2","author":"A Alshehri","year":"2015","unstructured":"Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e124.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1077_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijfoodmicro.2013.03.018","volume":"164","author":"ZJ Zhao","year":"2013","unstructured":"Zhao ZJ, Pan YZ, Liu QJ, Li XH. Exposure assessment of lovastatin in Pu-erh tea. Int J Food Microbiol. 2013;164(1):26\u201331.","journal-title":"Int J Food Microbiol"},{"issue":"1","key":"1077_CR63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/BF01610577","volume":"33","author":"P Bobek","year":"1994","unstructured":"Bobek P, Ozdin L, Kuniak L. Mechanism of hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats: reduction of cholesterol absorption and increase of plasma cholesterol removal. Z Ernahrungswiss. 1994;33(1):44\u201350.","journal-title":"Z Ernahrungswiss"},{"issue":"6","key":"1077_CR64","first-page":"313","volume":"34","author":"M Klimek","year":"2009","unstructured":"Klimek M, Wang S, Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T. 2009;34(6):313\u201327.","journal-title":"P T"},{"issue":"2","key":"1077_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","volume":"68","author":"P Basharat","year":"2016","unstructured":"Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016;68(2):234\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1077_CR66","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken). 2012;64(8):1233\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"1077_CR67","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi T, Rider LG, Pak K, et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"1077_CR68","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10(7):1537.","journal-title":"J Clin Med."},{"key":"1077_CR69","doi-asserted-by":"publisher","first-page":"108788","DOI":"10.1016\/j.abb.2021.108788","volume":"701","author":"ML Paz","year":"2021","unstructured":"Paz ML, Barrantes FJ. Cholesterol in myasthenia gravis. Arch Biochem Biophys. 2021;701:108788.","journal-title":"Arch Biochem Biophys"},{"issue":"10","key":"1077_CR70","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","volume":"26","author":"Y Handelsman","year":"2020","unstructured":"Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract. 2020;26(10):1196\u2013224.","journal-title":"Endocr Pract"},{"issue":"8","key":"1077_CR71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129\u201350.","journal-title":"Can J Cardiol"},{"issue":"3","key":"1077_CR72","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","volume":"30","author":"GF Watts","year":"2021","unstructured":"Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ. 2021;30(3):324\u201349.","journal-title":"Heart Lung Circ"},{"key":"1077_CR73","doi-asserted-by":"crossref","unstructured":"Loh WJ, Chan DC, Mata P, Watts GF. Familial hypercholesterolemia and elevated lipoprotein(a): cascade testing and other implications for contextual models of care. 2022;13.","DOI":"10.3389\/fgene.2022.905941"},{"issue":"8","key":"1077_CR74","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","volume":"79","author":"A Mehta","year":"2022","unstructured":"Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022;79(8):757\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1077_CR75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejim.2012.08.014","volume":"24","author":"M Greif","year":"2013","unstructured":"Greif M, Arnoldt T, von Ziegler F, et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur J Intern Med. 2013;24(1):75\u20139.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"1077_CR76","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.nmd.2021.10.006","volume":"31","author":"A Lucia","year":"2021","unstructured":"Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S. International Association for Muscle Glycogen Storage Disease study g. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord. 2021;31(12):1296\u2013310.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1077_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ncpneuro0988","volume":"5","author":"NE Gilhus","year":"2009","unstructured":"Gilhus NE. Is it safe to use statins in patients with myasthenia gravis? Nat Clin Pract Neurol. 2009;5(1):8\u20139.","journal-title":"Nat Clin Pract Neurol"},{"issue":"9","key":"1077_CR78","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","volume":"78","author":"SS Virani","year":"2021","unstructured":"Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1077_CR79","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1210\/clinem\/dgaa674","volume":"105","author":"CB Newman","year":"2020","unstructured":"Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020;105(12):3613.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"1077_CR80","doi-asserted-by":"publisher","first-page":"e000082","DOI":"10.1136\/bmjdrc-2015-000082","volume":"3","author":"WB Horton","year":"2015","unstructured":"Horton WB, Taylor JS, Ragland TJ, Subauste AR. Diabetic muscle infarction: a systematic review. BMJ Open Diabetes Res Care. 2015;3(1):e000082.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"1077_CR81","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1077_CR82","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ecl.2022.01.004","volume":"51","author":"CB Newman","year":"2022","unstructured":"Newman CB. Safety of statins and nonstatins for treatment of dyslipidemia. Endocrinol Metab Clin North Am. 2022;51(3):655.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"1077_CR83","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/art.40919","volume":"71","author":"E Tiniakou","year":"2019","unstructured":"\u2022 Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L. Use of proprotein convertase subtilisin\/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol. 2019;71(10):1723\u20136.\u00a0This study reported that the use of PCSK9 inhibitors in 8 patients with anti-HMGCR-positive IMNM was safe.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1077_CR84","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbus","year":"2020","unstructured":"Dyrbus K, Gasior M, Penson P, Ray KK, Banach M. Inclisiran-New hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16\u201327.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1077_CR85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.transci.2016.01.003","volume":"54","author":"M Mortzell Henriksson","year":"2016","unstructured":"Mortzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2\u201315.","journal-title":"Transfus Apher Sci"},{"issue":"8","key":"1077_CR86","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"1077_CR87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","volume":"22","author":"C Stefanutti","year":"2020","unstructured":"Stefanutti C. Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2020;22(8):38.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1077_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2125.2004.02095.x","volume":"58","author":"JJ Lilja","year":"2004","unstructured":"Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58(1):56\u201360.","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"1077_CR89","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395.","journal-title":"Circulation"},{"issue":"4","key":"1077_CR90","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"\u2022\u2022\u00a0Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361.\u00a0The NLA provides an updated definition of statin intolerance, and recommendations for management.","journal-title":"J Clin Lipidol"},{"issue":"19","key":"1077_CR91","doi-asserted-by":"publisher","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","volume":"7","author":"H Qu","year":"2018","unstructured":"Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(19):e009835.","journal-title":"J Am Heart Assoc"},{"key":"1077_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.006","volume":"299","author":"C Kennedy","year":"2020","unstructured":"Kennedy C, Koller Y, Surkova E. Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis. Atherosclerosis. 2020;299:1\u20138.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1077_CR93","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11845-021-02651-x","volume":"191","author":"H Wei","year":"2022","unstructured":"Wei H, Xin X, Zhang J, et al. Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Ir J Med Sci. 2022;191(2):719\u201325.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"1077_CR94","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.21743","volume":"66","author":"P Kaufmann","year":"2009","unstructured":"Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235\u201344.","journal-title":"Ann Neurol"},{"issue":"1","key":"1077_CR95","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","volume":"57","author":"R Laaksonen","year":"1995","unstructured":"Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57(1):62\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1077_CR96","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40292-022-00526-5","volume":"29","author":"CB Teo","year":"2022","unstructured":"Teo CB, Tan PY, Tay RYK, Khoo J, Watts GF, Loh WJ. Association between vitamin D supplementation and statin-associated muscle symptoms: a systematic review. High Blood Press Cardiovasc Prev. 2022;29(4):337\u201351.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"6","key":"1077_CR97","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","volume":"29","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Christopher-Stine L. Immune-mediated necrotizing myopathy associated with statins: history and recent developments. Curr Opin Rheumatol. 2017;29(6):604\u201311.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1077_CR98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mpmed.2021.10.011","volume":"50","author":"MJS Parker","year":"2022","unstructured":"Parker MJS, Lilleker JB, Chinoy H. Adult idiopathic inflammatory myopathies. Medicine (Baltimore). 2022;50(1):70\u20135.","journal-title":"Medicine (Baltimore)"},{"key":"1077_CR99","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3389\/fneur.2018.01035","volume":"9","author":"MR Grabler","year":"2018","unstructured":"Grabler MR, Weyen U, Juckel G, Tegenthoff M, Mavrogiorgou-Juckel P. Death anxiety and depression in amyotrophic lateral sclerosis patients and their primary caregivers. Front Neurol. 2018;9:1035.","journal-title":"Front Neurol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01077-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:36:31Z","timestamp":1701668191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01077-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01077-9","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"30 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}